Cantor Fitzgerald Forecasts Strong Price Appreciation for Progyny (NASDAQ:PGNY) Stock

Posted by Francis Steltz on Nov 7th, 2026

Progyny (NASDAQ:PGNY – Get Free Report) had its target price raised by research analysts at Cantor Fitzgerald from $31.00 to $35.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald‘s target price would indicate a potential upside of 0.46% from the stock’s previous close.

PGNY has been the topic of several other reports. Citigroup reissued a “market outperform” rating on shares of Progyny in a research report on Thursday. Barclays dropped their price target on shares of Progyny from $34.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 12th. Citizens Jmp increased their price target on shares of Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research note on Tuesday, September 8th. Wall Street Zen lowered shares of Progyny from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 31st. Finally, Weiss Ratings raised shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, October 8th. Eleven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and an average target price of $34.92.

Check Out Our Latest Analysis on PGNY

Progyny Stock Performance

Progyny stock traded up $0.47 during trading on Thursday, hitting $34.84. The company’s stock had a trading volume of 1,548,505 shares, compared to its average volume of 956,940. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of 31.96, a P/E/G ratio of 2.03 and a beta of 0.97. The stock’s fifty day moving average is $27.45 and its 200 day moving average is $24.59. Progyny has a 1-year low of $16.10 and a 1-year high of $35.50.

Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.21. The firm had revenue of $341.25 million for the quarter, compared to analyst estimates of $340.76 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the company earned $0.15 EPS. On average, research analysts anticipate that Progyny will post 1.25 EPS for the current fiscal year.

Insider Transactions at Progyny

In related news, COO Melissa B. Cummings sold 1,879 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total transaction of $52,612.00. Following the completion of the sale, the chief operating officer owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. This represents a 2.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kevin K. Gordon sold 11,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total transaction of $321,310.00. Following the completion of the transaction, the director owned 6,792 shares in the company, valued at $189,768.48. The trade was a 62.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 19,421 shares of company stock valued at $539,960. 9.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Progyny

Several institutional investors have recently bought and sold shares of PGNY. Bank of America Corp DE purchased a new position in shares of Progyny in the 2nd quarter valued at $17,264,000. Hsbc Holdings PLC purchased a new stake in Progyny during the 2nd quarter worth $760,000. AWM Investment Company Inc. purchased a new stake in Progyny during the 2nd quarter worth $6,343,000. Corient Private Wealth LP purchased a new stake in Progyny during the 2nd quarter worth $3,488,000. Finally, Squarepoint Ops LLC acquired a new stake in Progyny in the 2nd quarter valued at $1,705,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

More Progyny News

Here are the key news stories impacting Progyny this week:

Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share and revenue of $341.25 million, slightly above the cited consensus revenue estimate. Revenue grew 8.9% year over year, while earnings increased from $0.15 per share a year earlier. Read More.
Positive Sentiment: The company raised its full-year 2026 earnings guidance, a sign that management sees stronger earnings prospects. Read More.
Positive Sentiment: Several analysts raised their price targets following the results: Citizens JMP and Leerink Partners moved to $38, while Cantor Fitzgerald raised its target to $35 and maintained an overweight rating. These revisions reinforce a favorable analyst view, although the targets imply varying degrees of potential upside. Read More.
Neutral Sentiment: Coverage highlighted new client wins and margin expansion, but also noted a cautious market response. This suggests investors may be weighing growth and profitability improvements against expectations already reflected in the stock. Read More.

Progyny Company Profile

(Get Free Report)

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.